CoChat

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

Open access
Haderk, Franziska, Chou, Yu-Ting, Cech, Lauren, Fernández-Méndez, Celia, Yu, Johnny, Olivas, Victor, Meraz, Ismail M., Barbosa Rabago, Dora, Kerr, D. Lucas, Gomez, Carlos, Allegakoen, David V., Guan, Juan, Shah, Khyati N., Herrington, Kari A., Gbenedio, Oghenekevwe M., Nanjo, Shigeki, Majidi, Mourad, Tamaki, Whitney, Pourmoghadam, Yashar K., Rotow, Julia K., McCoach, Caroline E., Riess, Jonathan W., Gutkind, J. Silvio, Tang, Tracy T., Post, Leonard, Huang, Bo, Santisteban, Pilar, Goodarzi, Hani, Bandyopadhyay, Sourav, Kuo, Calvin J., Roose, Jeroen P., Wu, Wei, Blakely, Collin M., Roth, Jack A., Bivona, Trever G. · 2024 · Nature Communications

Published version of a preprint

Cited by 103

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-47423-0

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 36

  1. Bivona, T. G. & Doebele, R. C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472–478 (2016). · DOI · Paper page
  2. Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232–1251.e22 (2020). · DOI · Paper page
  3. Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860–874 (2020). · DOI · Paper page
  4. Feng, X. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer cell 25, 831–845 (2014). · DOI · Paper page
  5. Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013). · DOI · Paper page
  6. Moroishi, T., Hansen, C. G. & Guan, K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73–79 (2015). · DOI · Paper page
  7. Das, A., Fischer, R. S., Pan, D. & Waterman, C. M. YAP nuclear localization in the absence of cell-cell contact is mediated by a filamentous actin-dependent, myosin ii- and phospho-yap-independent pathway during extracellular matrix mechanosensing. J. Biol. Chem. 291, 6096–6110 (2016). · DOI · Paper page
  8. Miyazawa, A. et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem Biophys. Res Commun. 495, 2344–2349 (2018). · DOI · Paper page
  9. Ghasemi, H. et al. Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection. Ann. N. Y Acad. Sci. 1473, 48–61 (2020). · DOI
  10. Zhao, B., Kim, J., Ye, X., Lai, Z.-C. & Guan, K.-L. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 69, 1089–1098 (2009). · DOI · Paper page
  11. Bell, C. C. & Gilan, O. Principles and mechanisms of non-genetic resistance in cancer. Br. J. Cancer 122, 465–472 (2020). · DOI · Paper page
  12. Wilson, C. et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget 5, 7328–7341 (2014). · DOI · Paper page
  13. Hsia, D. A. et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160, 753–767 (2003). · DOI · Paper page
  14. Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Therapeutics 146, 132–149 (2015). · DOI · Paper page
  15. Knezevic, N., Tauseef, M., Thennes, T. & Mehta, D. The G protein betagamma subunit mediates reannealing of adherens junctions to reverse endothelial permeability increase by thrombin. J. Exp. Med. 206, 2761–2777 (2009). · doi:10.1084/jem.20090652
  16. Moroishi, T. et al. The hippo pathway kinases lats1/2 suppress cancer immunity. Cell 167, 1525–1539.e1517 (2016). · DOI · Paper page
  17. Meraz, I. M. et al. An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol. Res. 7, 1267–1279 (2019). · DOI · Paper page
  18. Aissa, A. F. et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 12, 1628 (2021). · DOI · Paper page
  19. Hu, C. et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 108, 1347–1356 (2017). · DOI
  20. Wang, W. et al. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 13, 524–532 (2015). · DOI · Paper page
  21. Lange, A. W. et al. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. J. Mol. Cell Biol. 7, 35–47 (2015). · DOI · Paper page
  22. LaCanna, R. et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J. Clin. Invest. 129, 2107–2122 (2019). · DOI · Paper page
  23. Holden, J. K. et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling. Cell Rep. 31, 107809 (2020). · DOI · Paper page
  24. Yap, T. A. et al. First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein(YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solidtumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. In AACR Annual Meeting (AACR, Orlando, Florida, 2023). · DOI
  25. Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313–324 (2021). · DOI · Paper page
  26. van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218–232 (2020). · DOI · Paper page
  27. Janse van Rensburg, H. J. & Yang, X. The roles of the Hippo pathway in cancer metastasis. Cell Signal 28, 1761–1772 (2016). · DOI
  28. Suzuki, K., Bose, P., Leong-Quong, R. Y. Y., Fujita, D. J. & Riabowol, K. REAP: A two minute cell fractionation method. BMC Res. Notes 3, 294 (2010). · DOI · Paper page
  29. Feng, S. et al. Improved split fluorescent proteins for endogenous protein labeling. Nat. Commun. 8, 370 (2017). · DOI · Paper page
  30. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012). · DOI · Paper page
  31. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003). · DOI · Paper page
  32. Guo, Y., Ding, X., Shen, Y., Lyon, G. J. & Wang, K. SeqMule: automated pipeline for analysis of human exome/genome sequencing data. Sci. Rep. 5, 14283 (2015). · DOI
  33. Hysenaj, L. et al. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv https://doi.org/10.1101/2021.06.01.446640 (2021). · DOI
  34. Haderk, F., Olivas, V. & Bivona, T. G. Immunohistochemistry to study YAP in human tissue samples. Methods Mol. Biol. 1893, 89–95 (2019). · DOI
  35. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011). · DOI · Paper page
  36. Le, B. L. et al. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Sci. Rep. 11, 12310 (2021). · DOI

Cited by

See all 103

Metadata

Authors
Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., Allegakoen, D. V., Guan, J., Shah, K. N., Herrington, K. A., Gbenedio, O. M., Nanjo, S., Majidi, M., Tamaki, W., Pourmoghadam, Y. K., Rotow, J. K., McCoach, C. E., Riess, J. W., Gutkind, J. S., Tang, T. T., Post, L., Huang, B., Santisteban, P., Goodarzi, H., Bandyopadhyay, S., Kuo, C. J., Roose, J. P., Wu, W., Blakely, C. M., Roth, J. A., & Bivona, T. G.
Venue
Nature Communications
Published
2024-05-03
Volume
15
Issue
1
Pages
3741-3741
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4396605932
Cited by
103
References
33
FWCI
18.05
Type
journal article
Language
en
Open access
gold
Licence
Funders
U.S. Department of Health & Human Services | NIH | National Cancer Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. https://app.cochat.ai/papers/10.1038/s41467-024-47423-0
The paper
Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., Allegakoen, D. V., Guan, J., Shah, K. N., Herrington, K. A., Gbenedio, O. M., Nanjo, S., Majidi, M., Tamaki, W., Pourmoghadam, Y. K., . . . Bivona, T. G. (2024). Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nature Communications. https://doi.org/10.1038/s41467-024-47423-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.